Nilsine Partners’s Biogen BIIB Stock Holding History

Nilsine Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-857	Closed	-$220K	–	324
2023 Q3	$220K	Buy	+857	New	+$229K	0.03%	315

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nilsine Partners's BIIB Position: Q4 2023 in Review

Nilsine Partners sold out of Biogen (BIIB) in Q4 2023, closing a stake of 857 shares — an estimated $220K sold.

Nilsine Partners first reported a position in BIIB in Q3 2023 and held it in 1 quarter. The position peaked at $220K in Q3 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

Nilsine Partners reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
Nilsine Partners sold 857 Biogen shares in Q4 2023, an estimated $220K.
Nilsine Partners first reported a position in Biogen in Q3 2023 and held it in 1 quarter.
Nilsine Partners's Biogen position peaked at $220K in Q3 2023.
1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Nilsine Partners's 13F filing for Q4 2023, filed 24 Jan 2024.